Gufic Biosciences Announces Special Window for Share Transfer and Dematerialization
Gufic Biosciences opens a special window for share transfer and dematerialisation of physical securities from Feb 05, 2026, to Feb 04, 2027. This facility is for transactions before April 01, 2019, including previously rejected transfers. Transferred securities will be in demat mode with a one-year lock-in.
This is a procedural announcement aimed at assisting shareholders with a specific type of transaction. It does not directly impact the company's financial performance, strategic direction, or operational activities, thus having a low impact on the company and its investors.
The announcement is a routine regulatory filing providing information about a special window for shareholders to regularize their physical share transfers and dematerialisation. It does not contain any financial performance indicators or strategic business updates that would influence sentiment.
Gufic Biosciences Limited has announced a special window for the re-lodgement of transfer deeds relating to physical securities and their dematerialisation. This initiative, in line with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, commenced on February 05, 2026, and will remain open for one year until February 04, 2027.
The special window is designed for the lodgement of physical securities transfer and demat for transactions executed before April 01, 2019. This includes cases where transfer requests were previously rejected, returned, or not attended to due to documentation or procedural deficiencies.
Shareholders wishing to utilize this facility must submit original certificates along with transfer deeds and relevant supporting documents. Securities transferred under this window will be mandatorily credited to the transferee in demat mode and will be subject to a lock-in period of one year from the date of registration of transfer. During this lock-in period, the securities cannot be transferred, lien-marked, or pledged. Shareholders can contact MUFG Intime India Private Limited, the company's Registrar and Transfer Agent, or Gufic Biosciences' corporate office for further assistance.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under shareholder meetings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.